Intravitreal Drug Delivery Capabilities

I-vation™ Intravitreal Implant
The I-vation™ Intravitreal Implant is a drug delivery platform made of a non-ferrous metal alloy. The small diameter of the implant enables minimally invasive placement through a 25 gauge needlestick. The unique helical shape maximizes the surface area available for drug coating and enables secure, sutureless anchoring of the implant against the sclera. The thin cap is designed to reside under the conjunctival membrane.

I-vation™ Sustained Drug Delivery System
The I-vation™ Sustained Drug Delivery System is capable of providing long-term drug delivery, thus replacing frequent intraocular injections. The I-vation system offers a great deal of versatility and flexibility for formulation and pharmacokinetics control. The system leverages SurModics' proven polymer technology with the design of the I-vation Intravitreal Implant. The I-vation sustained drug delivery system is positioned to take advantage of SurModics' patented drug delivery technology, which utilizes combinations of polymers (durable and/or biodegradable) and drug. 

The release of drug is controlled by the drug loading and composition of the polymer components, both of which influence the rate at which drug diffuses out of the coating. The elution rate is tunable from 6 months to 2 years. SurModics’ polymer systems allow for controlled delivery of a range of therapeutic molecules from small hydrophobic drugs to larger macromolecules and proteins.

I-vation™ TA*†
I-vation™ TA*† utilizes SurModics' I-vation™ sustained drug delivery system for site-specific delivery of the steroid triamcinolone acetonide (TA) into the posterior chamber of the eye. In June 2005, SurModics initiated a 31 patient, 36 month, Phase I clinical study. In this pilot Phase I study, results through 15-months post implantation suggest that I-vation TA* is safe and well tolerated. The design of I-vation TA* sustained drug delivery system facilitated both implantation and removal through a 0.5 mm sclerotomy. Preliminary efficacy data show that the treatment is promising in this study population. 

Click link on right to view the ARVO 2008 poster presentations.

*Disclaimer:  I-vation™ TA is a New Drug limited by US Federal Law to Investigational Use Only

 †Product Licensed to Merck & Co., Inc. for Future Development

Intravitreal Drug Delivery

Subretinal Drug Delivery

~~~~~~~~~~~~~~

I-vation Sustained Drug Delivery System (pdf)

Protein Delivery (pdf)

2008 ARVO I-vation TA Phase I
Study Results (pdf)

2008 ARVO Eureka Poster (pdf)